• PRO1184 first-in human study initiated and first patients dosed
• PRO1160 first-in-human study cleared for initiation in the US
• Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform

SUZHOU, China and WOODINVILLE, Wash., Jan. 3, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics, announced that 1) dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), and 2) the company received clearance from the U.S. Food and Drug Administration (FDA) to initiate the Phase 1 clinical trial evaluating PRO1160.

PRO1184

PRO1184 is an ADC comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload with ProfoundBio's novel, proprietary hydrophilic linker. The Phase 1 study will evaluate the safety, activity, and pharmacokinetics of PRO1184 in patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma. This first-in-human study is actively enrolling with multiple clinical trial sites across the United States.

PRO1160

PRO1160 is an antibody-drug conjugate (ADC) comprising a CD70-directed antibody conjugated to the exatecan payload with ProfoundBio's novel, proprietary hydrophilic linker. The Phase 1 study will evaluate the safety, activity, and pharmacokinetics of PRO1160 in patients with metastatic renal cell carcinoma, metastatic or relapsed nasopharyngeal carcinoma, or advanced non-Hodgkin lymphoma. In preclinical studies, PRO1160 demonstrated the potential to be a best-in-class ADC therapeutic with a wide therapeutic window.

"We are taking a major step forward with our next generation ADCs." said Naomi Hunder, MD, CMO of ProfoundBio. "Our preclinical data support the potential for improved safety and activity over prior programs targeting folate receptor alpha and CD70, based on our novel hydrophilic linker and exatecan payload. We are excited to bring these advancements to the clinic, where we hope to help a broader patient population due to a potentially wider therapeutic window and ability to target antigens with low-moderate or heterogeneous tumor expression."

"With two clinical-stage programs, ProfoundBio is poised to validate our novel, proprietary, and internally developed ADC technology platform in the clinic and to bring a series of ADCs with best- and/or first-in-class potential to patients with unmet medical need." said Baiteng Zhao, PhD, Co-founder, Chief Executive Officer, and Chair of the Board of ProfoundBio. "We conclude 2022 with several significant accomplishments including the FDA clearance of two INDs and a Series A+ funding round. I am very excited about the momentum and look forward to continued progress of our lead programs in the clinic as well as advancing more pipeline assets through preclinical development and making further breakthroughs in ADC technologies in 2023."

About ProfoundBio

ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China.

For more information, please visit www.profoundbio.com.